Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice
文献类型：期刊论文
| 刊名 | JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
 |
| 出版日期 | 2017 |
| 卷号 | 18 |
| 关键词 | RANDOMIZED PHASE-III NEOADJUVANT CHEMOTHERAPY ENCAPSULATED DOXORUBICIN 1ST-LINE CHEMOTHERAPY PROGNOSTIC MARKER PLUS DOCETAXEL COMBINATION CYCLOPHOSPHAMIDE TRASTUZUMAB PACLITAXEL Liposomal doxorubicin Breast cancer Adjuvant chemotherapy Therapeutic effect Toxic and side effects |
| ISSN号 | 1673-1581 |
| 其他题名 | Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice * |
| 英文摘要 | Breast cancer is one of the malignant tumors with the highest morbidity and mortality. It is helpful to reduce the rate of tumor recurrence and metastasis by treating breast cancer with adjuvant chemotherapy, so as to increase the cure rate or survival of patients. In recent years, liposomes have been regarded as a kind of new carrier for targeted drugs. Being effective for enhancing drug efficacy and reducing side effects, they have been widely used for developing anticancer drugs. As a kind of anthracycline with high anticancer activity, doxorubicin can treat or alleviate a variety of malignant tumors effectively when it is used on its own or in combination with other anticancer drugs. Although liposomal doxorubicin has been extensively used in the adjuvant chemotherapy of breast cancer, its exact therapeutic efficacy and side effects have not been definitely proven. Various clinical studies have adopted different combined regimes, dosages, and staging, so their findings differ to certain extent. This paper reviews the clinical application of liposomal doxorubicin in the adjuvant chemotherapy of breast cancer and illustrates therapeutic effects and side effects of pegylated liposomal doxorubicin (PLD) and non-PLD (NPLD) in clinical research, in order to discuss the strategies for applying these drugs in such adjuvant chemotherapy, looking forward to providing references for related research and clinical treatment in terms of dosage, staging, combined regimes, and analysis methods and so on. |
| 资助项目 | ["151" Excellent Middle-Aged and Talented Young Persons of Zhejiang Province, China] ; [Key Platform Technological Project of Zhejiang Medical Science and Hygiene, China] |
| 语种 | 英语 |
| CSCD记录号 | CSCD:5922974 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/52231]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 推荐引用方式 GB/T 7714 | . Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice[J]. JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B,2017,18. |
| APA | (2017).Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B,18. |
| MLA | "Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice".JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B 18(2017). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。